FDA-Approved Elacestrant Is Clinically Effective at Treating Advanced or Metastatic Breast Cancer

By Oncology Brothers - Last Updated: February 2, 2023

Aditya Bardia, MD, MPH, associate professor at Massachusetts General Hospital, Harvard Medical School, spoke with The Oncology Brothers about the EMERALD study. This randomized, open-label, active-controlled, multicenter trial found that elacestrant yields better progression-free survival compared with standard of care in ER+, HER2-metastatic breast cancer patients. The results of the study prompted the recent FDA approval of elecestrant, which is the first oral selective estrogen receptor degrader.



Latest News

May 30, 2023